ENDRA Life Sciences Inc.
Close on Oct 19, 2026
- Market cap
- $11.76M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 17, 2026 | After market close | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 31, 2026 | After market close | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Jul 9, 2025 | After market close | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 15, 2025 | After market close | – | $-1.86 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 31, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 15, 2024 | After market close | – | $-9.54 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 23, 2024 | After market close | – | $-0.08 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 14, 2024 | After market close | – | $-0.26 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 28, 2024 | After market close | – | $0.17 | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 14, 2023 | After market close | – | $-0.40 | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 14, 2023 | After market close | – | – | – |
| Q1 FY2023 Ended Mar 31, 2023 | May 15, 2023 | After market close | – | – | – |
Press releases
Announcements ENDRA Life Sciences filed with the SEC
PRESS RELEASE DATED AUGUST 17, 2026, FURNISHED HEREWITH
Results of operations · EX-99.1 to Form 8-K
Investor Presentation June 2026 CONFIDENTIAL | NOT FOR FURTHER DISTRIBUTION
Material agreement · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
PRESS RELEASE DATED JUNE 25, 2026
Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE DATED MARCH 31, 2026, FURNISHED HEREWITH
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE DATED MARCH 25, 2026
Exit or restructuring costs · Regulation FD disclosure · EX-99.1 to Form 8-K
ENDRA Life Sciences Closes Up to $14.4 Million Private
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
DESCRIPTION OF DIGITAL ASSET STRATEGY
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Absent federal regulations, there is a possibility that certain cryptocurrencies may be classified as “securities.” Any classification of a cryptocurrency as a “security” would subject us to additional regulation and could materially impact the operation of our business.
Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
We expect no revenue for the quarter ended June 30, 2025 and did not have revenue for the quarter ended June 30, 2024.
Results of operations · EX-99.1 to Form 8-K
ENDRA Life Sciences Provides a Business Update and Reports First Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
ENDRA Life Sciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides a Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
ENDRA Life Sciences Announces Enhanced Strategy to Enable the Early
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
ENDRA Life Sciences Regains Compliance with Nasdaq Minimum Bid Price Requirement
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
ENDRA Life Sciences Reports Third Quarter 2024 Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
ENDRA Life Sciences Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirements
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
ENDRA Life Sciences Reports Second Quarter 2024 Financial Results and Provides a Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Second Quarter 2024 Financial Results Conference Call
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
ENDRA Life Sciences Announces Reverse Stock Split
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
ENDRA Life Sciences Announces Leadership Changes
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
ENDRA Life Sciences Announces Pricing of $8.0 Million Public Offering
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
ENDRA Provides Update Following In-person Meeting with FDA
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
ENDRA Life Sciences Reports First Quarter 2024 Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
We expect no revenue for the quarter ended March 31, 2024 and did not have any revenue for the quarter ended March 31, 2023.
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
ENDRA Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
ENDRA Life Sciences Reports Third Quarter 2023 Financial Results and
Results of operations · EX-99.1 to Form 8-K
ENDRA Life Sciences Reports Second Quarter 2023 Financial Results and
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
ENDRA Life Sciences Submits De Novo Request for its TAEUS ® System Liver Fat Application to the U.S. FDA
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
ENDRA Life Sciences Announces Adjournment of
Other events · EX-99.1 to Form 8-K
ENDRA Life Sciences Reports First Quarter 2023 Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE, DATED APRIL 28, 2023,
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE, DATED MAY 2, 2023
Material agreement · Regulation FD disclosure · EX-99.2 to Form 8-K
We expect no revenue for the quarter ended March 31, 2023 and did not have revenue for the quarter ended March 31, 2022.
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
ENDRA Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
ENDRA Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
ENDRA Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE DATED MAY 12, 2022, FURNISHED HEREWITH.
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE DATED APRIL 21, 2022, FURNISHED HEREWITH.
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
ENDRA Life Sciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
ENDRA Life Sciences Provides Update on U.S. Regulatory Strategy for its TAEUS ® System
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Listing notice · Regulation FD disclosure · EX-99.1 to Form 8-K